Plain-English translation of NCT04985058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This trial is collecting real-world information from breast cancer patients taking abemaciclib combined with hormone therapy. Researchers want to understand how well this medication combination works and what side effects patients actually experience in everyday practice. You would report your side effects online, and depending on which group you're in, you may also receive personalized supportive messages for each side effect you report.
While this medication has been approved by regulators, researchers want to learn more about how it performs in real patients outside of controlled clinical trials, and whether providing personalized digital support helps patients manage side effects better.
You likely qualify if…
You likely don't qualify if…
You would register on a secure online platform using your patient ID and email address. At regular intervals, you would log in and report any side effects you're experiencing from the medication and hormone therapy. After each report, you'll receive an acknowledgement and a reminder to stay in contact with your doctor—and if you're selected for the support group, you'll also get personalized encouragement messages for the side effects you report. The study involves no additional clinic visits or procedures beyond your regular cancer care.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Greece
Sponsor
Hellenic Cooperative Oncology Group
Enrollment target
~108 participants
Started
October 2021
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elena Fountzilas, MD, PhD
Hellenic Cooperative Oncology Group
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.